ELDER WILLIAM ROBERT

CFO William Robert Elder buys 3,500 shares ($29.2K) across 2 transactions at CervoMed; 3 other insiders also bought within 14 days.

William Robert Elder, CFO, General Counsel & Secretary, executed 2 separate purchases totaling 3,500 shares for $29,250.00 at an average price of $8.36, increasing his holdings by 38.9% from 9,000 to 12,500 shares. This activity is part of a cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated confidence at current levels. However, Elder's personal track record across other holdings shows mixed outcomes: his prior cross-ticker buys averaged a 30-day return of -15.8% and a 90-day return of -20.3%, with a 50% win rate. At CervoMed specifically, his prior 2 completed buys posted a 90-day timing pattern of 1 out of 2 well-timed, with outcomes ranging from +11.1% to -51.8% over 90 days. The company is unprofitable (net income: $-7.7M in the latest period), though annual revenue is growing at +36.3%, creating a tension between growth trajectory and near-term losses that may warrant scrutiny of the cluster buy's durability.

CFO William Robert Elder buys 3,500 shares of CervoMed (CRVO) at $7.44 as stock trades -49.3% from 52-week high; cluster buy detected.

CFO William Robert Elder purchased 3,500 shares at $7.44 on 2025-11-12, increasing his holdings by 63.6% to 9,000 shares total. The timing is notable: the stock currently trades at $7.25, down 49.3% from its 52-week high of $14.29 and down 28.4% over the past 90 days. However, Elder's own prior purchase history at CRVO shows mixed results—his last buy on 2025-05-14 delivered a -15.8% 30-day return and his August 2024 buy yielded a -51.8% 90-day return—suggesting limited predictive power. A cluster pattern exists, with 2 other insiders also buying within 14 days. The company remains unprofitable with a net loss of $7,726,639.00 over the latest fiscal year despite strong annual revenue growth of 36.3%, creating ambiguity about whether this accumulation reflects conviction in a turnaround or simply opportunistic buying at depressed levels.

CFO William Robert Elder buys 4,233 shares of CRVO at $8.46, increasing stake 334.1%; stock now down 14.0% in 30 days, trading -66.3% from 52-week high of $24.72.

Elder's purchase of 4,233 shares ($35,811.18 total) represents a significant 334.1% increase to his stake at CervoMed, suggesting material commitment at this price point. However, the timing is concerning: his only prior buy at CRVO (2024-08-27) saw a -51.8% return at the 90-day mark, and the stock has fallen 14.0% in the 30 days since this latest transaction, trading -66.3% below its 52-week high of $24.72. The company remains unprofitable on a full-year basis (net income of $-4,894,034.00) despite recent revenue growth of 36.3%, indicating continued operational challenges. The cross-ticker pattern is also unfavorable: Elder's single prior open-market buy across all tickers posted a -15.7% 30-day return and -51.8% 90-day return, with a 0.00% win rate at 90 days.

CFO William Robert Elder buys 1,000 CRVO shares at $18.16 (Aug 27); holdings triple to 1,267 shares; stock -35.7% from 52-week high.

William Robert Elder, CFO & GC, purchased 1,000 shares at $18.16 on 2024-08-27, increasing his holdings by 374.5% from 267 to 1,267 shares. This is a material increase in his personal stake at a price significantly above the current market price of $16.67, and notably above the 52-week low of $4.28, suggesting the purchase was made during a period of relative strength. However, the company is unprofitable with net income of $-2,316,905.00 for the latest quarter, and the stock has declined 35.7% from its 52-week high of $25.93. The purchase warrants examination of whether this reflects genuine confidence in a recovery trajectory or other considerations, particularly given the company's current negative earnings profile and recent price trajectory (30-day +18.8%, 90-day -15.7%).